LDN and Chronic Fatigue Syndrome
June 13, 2009
Low-Dose Naltrexone for Fibromyalgia & Chronic Fatigue Syndrome
TREATMENT BRIEF: Anti-Addiction Drug Shows Promise
Low-dose naltrexone (LDN) is getting a lot of attention as a treatment for fibromyalgia (FMS) and chronic fatigue syndrome (CFS or ME/CFS), as well as a host of other conditions. A normal doses, it's an anti-addiction drug, but at very low doses it acts very differently.
LDN works on the central nervous system, which is believed to be disordered in FMS and ME/CFS. It's also believed to reduce inflammation, which can be a problem in ME/CFS and with disorders that are common in people with FMS (FMS is not considered an inflammatory condition.)
An exciting thing about LDN is that it's inexpensive and already on the market. Anecdotal evidence so far is very promising, as is the first clinical trial for FMS.
Project LDN FUNDING CLINICAL TRIALS
, 2009
http://www.fibrocenter.com/
http://autoimmunedisease.suite101.com/article.cfm/fibromyalgia_treatment
Low dose naltrexone is a prescription drug used off label for MS and other medical conditions. Subjects are needed for the first clinical trial of LDN in fibromyalgia.
Investigators at Stanford University are recruiting patients with fibromyalgia living in the Stanford area for a clinical trial. The study is being conducted by Dr. Jarred Younger and his colleagues at the Stanford Packard Center for Translational Research in Medicine. In this double blind, placebo-controlled clinical trial, researchers are evaluating the effects of low dose naltrexone (LDN) in the autoimmune disorder fibromyalgia.
Read more